{"id":8515,"date":"2025-12-08T15:15:10","date_gmt":"2025-12-08T15:15:10","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8515"},"modified":"2025-12-08T15:15:10","modified_gmt":"2025-12-08T15:15:10","slug":"structure-therapeutics-reports-breakthrough-weight-loss-results-for-oral-glp-1-candidate-aleniglipron","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/12\/08\/structure-therapeutics-reports-breakthrough-weight-loss-results-for-oral-glp-1-candidate-aleniglipron\/","title":{"rendered":"Structure Therapeutics Reports Breakthrough Weight-Loss Results for Oral GLP-1 Candidate Aleniglipron"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Phase 2b and ACCESS II studies show up to 15.3% weight reduction with promising tolerability, positioning aleniglipron as a potential best-in-class oral therapy for obesity.<\/h4>\n\n\n\n<p>Structure Therapeutics (GPCR) has announced highly encouraging topline results from its multi-study ACCESS clinical program evaluating <strong>aleniglipron<\/strong>, an investigational once-daily oral GLP-1 receptor agonist designed to treat obesity and overweight patients with weight-related comorbidities. The data released include 36-week results from the Phase 2b ACCESS core study, the exploratory ACCESS II study evaluating higher doses, interim insights from a Body Composition study, and early findings from an ongoing open-label extension (OLE).<\/p>\n\n\n\n<p>Across both controlled studies, aleniglipron demonstrated <strong>robust, clinically meaningful, and dose-dependent weight loss<\/strong> with a tolerability profile consistent with existing GLP-1 therapies, making it one of the most promising oral candidates under development.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Phase 2b ACCESS: Up to 12.1% Mean Weight Loss<\/strong><\/h3>\n\n\n\n<p>The randomized, double-blind Phase 2b trial enrolled 230 adults living with obesity (BMI \u2265 30) or overweight with comorbidities (BMI \u2265 27). After 36 weeks, aleniglipron achieved:<\/p>\n\n\n\n<ul>\n<li><strong>11.3% placebo-adjusted weight loss at 120 mg<\/strong> (27.3 lbs; p&lt;0.0001)<\/li>\n\n\n\n<li><strong>Mean weight loss of 12.1%<\/strong> in the 120 mg arm<\/li>\n\n\n\n<li><strong>86%<\/strong> of patients achieving \u22655% weight loss<\/li>\n\n\n\n<li><strong>70%<\/strong> achieving \u226510% weight loss<\/li>\n<\/ul>\n\n\n\n<p>Patients also saw clinically meaningful improvements in systolic blood pressure and HbA1c. Treatment discontinuations related to adverse events averaged <strong>10.4%<\/strong>, consistent with the GLP-1 class.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>ACCESS II: Higher Doses Deliver Up to 15.3% Weight Loss<\/strong><\/h3>\n\n\n\n<p>ACCESS II evaluated doses up to 240 mg across 85 participants. At 36 weeks:<\/p>\n\n\n\n<ul>\n<li><strong>Placebo-adjusted reductions reached 15.3%<\/strong> at 240 mg (35.5 lbs; p&lt;0.0001)<\/li>\n\n\n\n<li>All doses achieved statistical significance<\/li>\n\n\n\n<li>Weight loss showed <strong>no signs of plateauing<\/strong>, suggesting continued benefit beyond 36 weeks.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Improved Tolerability with Lower Starting Dose<\/strong><\/h3>\n\n\n\n<p>A separate Body Composition study using a <strong>2.5 mg starting dose<\/strong> showed significantly better tolerability in early titration, with <strong>no treatment discontinuations<\/strong> through the 5 mg phase. This supports a refined dosing schedule for Phase 3.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Open-Label Extension: Continued Weight Loss at 44 Weeks<\/strong><\/h3>\n\n\n\n<p>Preliminary OLE results show <strong>sustained weight loss beyond Week 36<\/strong>, further underscoring aleniglipron\u2019s potential durability.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A Potential Oral Backbone Therapy for Obesity<\/strong><\/h3>\n\n\n\n<p>CEO Dr. Raymond Stevens said the data demonstrate \u201ccompetitive, dose-dependent weight loss with no plateau,\u201d positioning aleniglipron as a scalable oral therapy that could meaningfully expand access to GLP-1 treatments.<\/p>\n\n\n\n<p>With obesity affecting more than 650 million people globally, experts believe aleniglipron could become a transformative option\u2014if Phase 3 results align with this promising early profile.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/12\/08\/nasdaq-rises-ahead-of-fed-meeting-as-tech-stocks-rally-and-ma-activity-heats-up\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Nasdaq Rises Ahead of Fed Meeting as Tech Stocks Rally and M&amp;A Activity Heats Up<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phase 2b and ACCESS II studies show up to 15.3% weight reduction with promising tolerability, positioning aleniglipron as a potential best-in-class oral therapy for obesity. Structure Therapeutics (GPCR) has announced highly encouraging topline results from its multi-study ACCESS clinical program evaluating aleniglipron, an investigational once-daily oral GLP-1 receptor agonist designed to treat obesity and overweight [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[308,360],"tags":[865,421,416,418,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8515"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8515"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8515\/revisions"}],"predecessor-version":[{"id":8516,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8515\/revisions\/8516"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8515"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}